AACR 2024 | Sequential bortezomib and temozolomide in recurrent glioblastoma

Mohummad Rahman, PhD, University of Bergen, Bergen, Norway, discusses findings from a Phase Ib/II trial (NCT03643549) of sequential administration of bortezomib prior to temozolomide in patients with glioblastoma. The trial aimed to identify mechanisms underlying objective responses. The treatment was safe, and interim analysis confirms clinical benefit, supporting ongoing recruitment. The study demonstrates promising safety and efficacy profiles in recurrent GBM. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.